Arrowstreet Capital
CTKB icon

Arrowstreet Capital’s Cytek Biosciences CTKB Stock Holding History

Arrowstreet Capital’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.31M Buy
973,833
+653,924
+204% +$2.79M ﹤0.01% 1334
2026
Q1 		$1.4M Sell
319,909
-41,768
-12% -$197K ﹤0.01% 1476
2025
Q4 		$1.83M Buy
361,677
+387
+0.1% +$1.8K ﹤0.01% 1434
2025
Q3 		$1.25M Buy
361,290
+217,038
+150% +$815K ﹤0.01% 1547
2025
Q2 		$490K Buy
144,252
+96,098
+200% +$320K ﹤0.01% 1752
2025
Q1 		$193K Buy
+48,154
New +$250K ﹤0.01% 1743

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Arrowstreet Capital's CTKB Position: Q2 2026 in Review

Arrowstreet Capital increased its Cytek Biosciences (CTKB) stake by 204% in Q2 2026, buying an estimated $2.79M and bringing the position to 973,833 shares worth $4.31M. The position accounts for ﹤0.01% of the portfolio, ranked #1334.

Arrowstreet Capital first reported a position in CTKB in Q1 2025 and has held it in 6 quarters since. 154 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Arrowstreet Capital held 973,833 shares of Cytek Biosciences worth $4.31M as of Q2 2026.
  • Arrowstreet Capital bought 653,924 Cytek Biosciences shares in Q2 2026, an estimated $2.79M.
  • Cytek Biosciences made up ﹤0.01% of Arrowstreet Capital's portfolio in Q2 2026, its #1334 holding.
  • Arrowstreet Capital first reported a position in Cytek Biosciences in Q1 2025 and has held it in 6 quarters since.
  • 154 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.